Cardiac Effects in Children of Hypertensive Mothers: A Literature Review

Gabrielle Amar1, Josef Kusayev1, William H Frishman1

  • 1From the Department of Medicine, New York Medical College, Valhalla, NY.

Cardiology in Review
|April 18, 2025
PubMed

Insights

Preeclampsia (PE) in pregnancy can cause lasting heart changes in children, including structural and functional issues. More research is needed to understand these effects and enable early intervention for affected infants.

Area of Science:

  • Cardiovascular Science
  • Perinatal Medicine
  • Developmental Biology

Background:

  • Preeclampsia (PE) affects up to 8% of pregnancies, causing hypertension.
  • In utero PE exposure is linked to cardiac changes in neonates, such as increased left ventricular mass and myocardial hypertrophy.
  • Long-term cardiovascular effects in offspring are inconsistent, but some studies suggest persistent systolic and diastolic dysfunction into adulthood.

Purpose of the Study:

  • To review the cardiac manifestations in offspring exposed to preeclampsia in utero.
  • To highlight knowledge gaps regarding molecular pathways linking PE to offspring cardiovascular outcomes.
  • To increase awareness for early intervention opportunities in this high-risk population.

Main Methods:

  • Literature review synthesizing existing research on PE and offspring cardiovascular health.
  • Analysis of studies investigating fetal developmental programming due to intrauterine conditions.
  • Examination of evidence linking PE to altered cardiac remodeling and vascular resistance, independent of fetal growth restriction.

Main Results:

  • Offspring exposed to PE exhibit cardiac structural and functional changes, including increased left ventricular mass and hypertrophy.
  • Evidence suggests a potential for long-term cardiovascular risks, such as systolic and diastolic dysfunction, persisting into adolescence and adulthood.
  • Mechanisms involved in PE's impact on offspring cardiovascular health include placental insufficiency, angiogenic imbalance, oxidative stress, and epigenetic modifications.

Conclusions:

  • Preeclampsia exposure during pregnancy significantly impacts offspring cardiovascular development.
  • Further research is crucial to elucidate the molecular pathways and long-term consequences.
  • Early detection and intervention strategies are needed for infants born to mothers with preeclampsia.

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
475
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
379
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
511